Table 3.
The Values of Lymphocytes at Baseline and After 6 Months of Anti-TNFa Treatment
| Cells | ADA Group Week 0 | ETN Group Week 0 | IFN Group Week 0 | Normal Value in Donors Age Matched | P Value | ADA Group Week 24 | ETN Group Week 24 | IFN Group Week 24 | P Value |
|---|---|---|---|---|---|---|---|---|---|
| CD3+ | 1734±657 | 1725±688 | 1724±637 | 1100-1700 | NS | 1838±632 | 1653±736 | 1645±624 | NS |
| CD3+/CD4+ | 1734±657 | 1134±317 | 1158±366 | 650-1400 | NS | 1250±496 | 1065±562 | 1067±446 | NS |
| CD3+/CD8+ | 470±210 | 445±218 | 480±205 | 320-900 | NS | 520±230 | 489±223 | 534±321 | NS |
| CD19+ | 268±89 | 245±92 | 259±91 | 200-400 | NS | 273±143 | 261±202 | 255±174 | NS |
| CD20+ | 198±156 | 191±146 | 188±126 | 150-400 | NS | 193±179 | 164±85 | 99±17 | NS |
| CD19+/CD38+ | 234±143 | 223±133 | 214±163 | 150-400 | NS | 240±155 | 109±74 | 79±15 | NS |
| CD16+/56+ | 211±72 | 217±68 | 213±67 | 200-400 | NS | 219±87 | 211±54 | 210±45 | NS |
| CD14+HLADR+% | 57±12 | 55±14 | 59±12 | 50-90 | NS | 54.6±10.4 | 48.4±15.7 | 40.7±16.5 | <0.039 |
| CD14+HLADR+ | 345±213. | 335±223 | 349±209 | 300-400 | NS | 326±214 | 311±230. | 246±78 | <0.05 |